Nuclear Hormone Receptor 4A/NR4A Activator

BRF110 is an orally active, blood-brain barrier-penetrant Nurr1-RXRα heterodimer activator with an EC₅₀ of 0.9 μM in human systems. BRF110 increases the mRNA level of BDNF, upregulates the transcription of TH, AADC and GCH1 to elevate striatal dopamine levels. BRF110 exhibits neuroprotective activity against MPP⁺-induced cytotoxicity. BRF110 prevents dopaminergic neuron death, protects nerve cells from toxic damage, and improves motor coordination in mouse models. BRF110 can be used in research related to Parkinson's disease.

Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.

IP7e (Standard) is the analytical standard of IP7e (HY-110274). This product is intended for research and analytical applications. IP7e is a potent, brain-penetrant and orally active Nurr1 activator with an EC₅₀ value of 3.9 nM.